AMPK Activation
An innovative treatment for lifestyle and age-related diseases
Scientific concept
The global increase in obesity and an aging population promote type 2 diabetes, cardiovascular disease, fatty liver/NASH, chronic kidney disease, inflammatory conditions and certain cancers
“Pharmacological activation of AMPK mimics exercise & caloric restriction – mitigates multiple diseases associated with a sedentary lifestyle and aging”
R&D
Betagenon explores innovative pharmacological activation of AMPK to develop novel and safe therapies
About AMPK
A key sensor & regulator of energy charge – Activated by Exercise & Caloric restriction
0304
Our lead AMPK activator mimics the multiple beneficial health effects of exercise and caloric restriction
What we do
Betagenon is a clinical stage company that develops its proprietary first in class AMPK activators as novel innovative treatments for major diseases to reach commercial deals with relevant financial benefits
Betagenon is financed by private Investors:
Partnering
Betagenon is now actively seeking partners for the further clinical development AMPK activator O304 and of novel AMPK activator compounds